Drug eluting stents: Friend or foe? A review of cellular mechanisms behind the effects of paclitaxel and sirolimus eluting stents

Subroto Chatterjee, Ambarish Pandey

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Coronary artery disease continues to be an important cause of mortality and morbidity. Sirolimus and paclitaxel cluting stents have become an important treatment for patients undergoing revascularization from coronary blockages. These drug eluting stents have enjoyed great success initially in preventing recurrences of adverse cardiac events and decreasing the incidences of repeat revascularizations. However, adverse effects, such as thrombosis, emanating from the use of these drug eluting stents has recently come to focus. Hence a better understanding of the mechanism of action of these drugs in preventing restenosis is important for the long term success and potential betterment of drug eluting stent technology. Herein we review and discuss the pathophysiology of restenosis, the basic mechanism of action of sirolimus and paclitaxel eluting stents and their limitations so as to create a scope for more efficient and novel drug eluting stents in the future.

Original languageEnglish (US)
Pages (from-to)554-566
Number of pages13
JournalCurrent Drug Metabolism
Volume9
Issue number6
DOIs
StatePublished - Jul 1 2008
Externally publishedYes

Fingerprint

Drug-Eluting Stents
Stents
Sirolimus
Paclitaxel
Pharmaceutical Preparations
Coronary Artery Disease
Thrombosis
Technology
Morbidity
Recurrence
Mortality
Incidence
Therapeutics

Keywords

  • Arterial/aortic smooth muscle cells
  • Heart disease
  • Paclitaxel
  • Re-endothelialization
  • Sirolimus
  • Stents

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry

Cite this

Drug eluting stents : Friend or foe? A review of cellular mechanisms behind the effects of paclitaxel and sirolimus eluting stents. / Chatterjee, Subroto; Pandey, Ambarish.

In: Current Drug Metabolism, Vol. 9, No. 6, 01.07.2008, p. 554-566.

Research output: Contribution to journalReview article

@article{8a05d2a448534b8e9df7694cf1648416,
title = "Drug eluting stents: Friend or foe? A review of cellular mechanisms behind the effects of paclitaxel and sirolimus eluting stents",
abstract = "Coronary artery disease continues to be an important cause of mortality and morbidity. Sirolimus and paclitaxel cluting stents have become an important treatment for patients undergoing revascularization from coronary blockages. These drug eluting stents have enjoyed great success initially in preventing recurrences of adverse cardiac events and decreasing the incidences of repeat revascularizations. However, adverse effects, such as thrombosis, emanating from the use of these drug eluting stents has recently come to focus. Hence a better understanding of the mechanism of action of these drugs in preventing restenosis is important for the long term success and potential betterment of drug eluting stent technology. Herein we review and discuss the pathophysiology of restenosis, the basic mechanism of action of sirolimus and paclitaxel eluting stents and their limitations so as to create a scope for more efficient and novel drug eluting stents in the future.",
keywords = "Arterial/aortic smooth muscle cells, Heart disease, Paclitaxel, Re-endothelialization, Sirolimus, Stents",
author = "Subroto Chatterjee and Ambarish Pandey",
year = "2008",
month = "7",
day = "1",
doi = "10.2174/138920008784892119",
language = "English (US)",
volume = "9",
pages = "554--566",
journal = "Current Drug Metabolism",
issn = "1389-2002",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Drug eluting stents

T2 - Friend or foe? A review of cellular mechanisms behind the effects of paclitaxel and sirolimus eluting stents

AU - Chatterjee, Subroto

AU - Pandey, Ambarish

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Coronary artery disease continues to be an important cause of mortality and morbidity. Sirolimus and paclitaxel cluting stents have become an important treatment for patients undergoing revascularization from coronary blockages. These drug eluting stents have enjoyed great success initially in preventing recurrences of adverse cardiac events and decreasing the incidences of repeat revascularizations. However, adverse effects, such as thrombosis, emanating from the use of these drug eluting stents has recently come to focus. Hence a better understanding of the mechanism of action of these drugs in preventing restenosis is important for the long term success and potential betterment of drug eluting stent technology. Herein we review and discuss the pathophysiology of restenosis, the basic mechanism of action of sirolimus and paclitaxel eluting stents and their limitations so as to create a scope for more efficient and novel drug eluting stents in the future.

AB - Coronary artery disease continues to be an important cause of mortality and morbidity. Sirolimus and paclitaxel cluting stents have become an important treatment for patients undergoing revascularization from coronary blockages. These drug eluting stents have enjoyed great success initially in preventing recurrences of adverse cardiac events and decreasing the incidences of repeat revascularizations. However, adverse effects, such as thrombosis, emanating from the use of these drug eluting stents has recently come to focus. Hence a better understanding of the mechanism of action of these drugs in preventing restenosis is important for the long term success and potential betterment of drug eluting stent technology. Herein we review and discuss the pathophysiology of restenosis, the basic mechanism of action of sirolimus and paclitaxel eluting stents and their limitations so as to create a scope for more efficient and novel drug eluting stents in the future.

KW - Arterial/aortic smooth muscle cells

KW - Heart disease

KW - Paclitaxel

KW - Re-endothelialization

KW - Sirolimus

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=47749154449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47749154449&partnerID=8YFLogxK

U2 - 10.2174/138920008784892119

DO - 10.2174/138920008784892119

M3 - Review article

C2 - 18680476

AN - SCOPUS:47749154449

VL - 9

SP - 554

EP - 566

JO - Current Drug Metabolism

JF - Current Drug Metabolism

SN - 1389-2002

IS - 6

ER -